Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Cybersecurity ETF vs TransMedics Group Inc — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.41, while TransMedics Group Inc trades at $87.42 (market cap $3.10B). The key difference: First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| CIBR | TMDX | |
|---|---|---|
52-Week High | $100.60 | $150.42 |
52-Week Low | $60.74 | $61.99 |
Market Cap | — | $3.10B |
Sector | — | Technology |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIBR trades at $100.86, up 0.26% today, with strong bullish momentum from moving averages but overbought RSI signals. The cybersecurity ETF has outperformed the S&P 500 by 3:1 year-to-date, benefiting from AI-driven security spending growth exceeding $300 billion in 2026. Recent institutional activity shows mixed sentiment with Bank of America reducing its stake while First Trust Advisors increased its position by 12.4%.
Outlook remains positive given cybersecurity's essential role in AI expansion, though high RSI levels suggest near-term consolidation risk. The sector's defensive growth characteristics and increasing attack surfaces provide long-term tailwinds, but concentrated tech exposure and valuation concerns warrant monitoring.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
